Mereo BioPharma to Participate in Fireside Chat at the 21st Annual Needham Virtual Healthcare Conference
April 06 2022 - 7:00AM
Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the
“Company”), a clinical-stage biopharmaceutical company focused on
oncology and rare diseases, today announced that Dr. Denise
Scots-Knight, Chief Executive Officer of Mereo, will participate in
a fireside chat at the 21st Annual Needham Virtual Healthcare
Conference on Wednesday, April 13, 2022, at 12:45pm Eastern Time.
A live audio webcast of the fireside chat can be
accessed through the Investors section of the Company’s website at
www.mereobiopharma.com/investors. An archived replay of the
webcast will be available on the Company’s website for two weeks
following the live presentation.
About Mereo BioPharmaMereo
BioPharma is a biopharmaceutical company focused on the development
of innovative therapeutics that aim to improve outcomes for
oncology and rare diseases and plans to commercialize selected rare
disease programs. The Company has developed a portfolio of six
clinical stage product candidates. Mereo’s lead oncology product
candidate, etigilimab (anti-TIGIT), has advanced into an open label
Phase 1b/2 basket study evaluating anti-TIGIT in combination with
an anti-PD-1 in a range of tumor types including three rare tumors
and three gynecological carcinomas, cervical, ovarian, and
endometrial carcinomas. The Company’s second oncology product,
navicixizumab, for the treatment of late line ovarian cancer, has
completed a Phase 1 study and has been partnered with OncXerna
Therapeutics, Inc., formerly Oncologie, Inc. The Company has two
rare disease product candidates, alvelestat for the treatment of
severe Alpha-1 antitrypsin deficiency (AATD) and Bronchiolitis
Obliterans Syndrome (BOS), and setrusumab for the treatment of
osteogenesis imperfecta (OI). Alvelestat has recently received U.S.
Orphan Drug Designation for the treatment of AATD and is being
investigated in an ongoing Phase 2 proof-of-concept study in the
U.S. and Europe, with top-line data expected in early Q2 2022. The
Company’s partner, Ultragenyx Pharmaceutical, Inc., is expected to
initiate a pivotal Phase 2/3 pediatric study and young adult study
(5-25 years old) for setrusumab in OI in H1 2022.
Forward-Looking StatementsThis
press release contains “forward-looking statements.” All statements
other than statements of historical fact contained in this press
release are forward-looking statements within the meaning of
Section 27A of the United States Securities Act of 1933, as amended
(the “Securities Act”), and Section 21E of the United States
Securities Exchange Act of 1934, as amended (the “Exchange Act”).
Forward-looking statements relate to future events, including, but
not limited to, statements regarding future clinical development,
efficacy, safety, and therapeutic potential of clinical product
candidates, including expectations as to reporting of data, conduct
and timing and potential future clinical activity and milestones
and expectations regarding the initiation, design and reporting of
data from clinical trials. Forward-looking statements are often
identified by the words “believe,” “expect,” “anticipate,” “plan,”
“intend,” “foresee,” “should,” “would,” “could,” “may,” “estimate,”
“outlook” and similar expressions, including the negative thereof.
The absence of these words, however, does not mean that the
statements are not forward-looking. These forward-looking
statements are based on the Company’s current expectations, beliefs
and assumptions concerning future developments and involve risks
and uncertainties that could cause actual results, performance, or
events to differ materially from those expressed or implied in such
statements. You should carefully consider the foregoing factors and
the other risks and uncertainties that affect the Company’s
business, including those described in the “Risk Factors” section
of its latest Annual Report on Form 20-F, reports on Form 6-K and
other documents furnished or filed from time to time by the Company
with the Securities and Exchange Commission. You should not place
undue reliance on any forward-looking statements, which speak only
as of the date hereof. The Company undertakes no obligation to
publicly update or revise any forward-looking statements after the
date they are made, whether as a result of new information, future
events or otherwise, except to the extent required by law.
Mereo BioPharma Contacts: |
|
|
Mereo |
|
+44 (0)333 023 7300 |
Denise Scots-Knight, Chief Executive Officer |
|
|
Christine Fox, Chief Financial Officer |
|
|
|
|
|
Burns McClellan (Investor Relations Adviser to
Mereo) |
|
+01 212 213 0006 |
Lee Roth |
|
Investors |
|
|
investors@mereobiopharma.com |
|
|
Mereo BioPharma (NASDAQ:MREO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Mereo BioPharma (NASDAQ:MREO)
Historical Stock Chart
From Jul 2023 to Jul 2024